secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001628280-25-043290
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

C4 Therapeutics Enters Clinical Trial Collaboration with Pfizer for Multiple Myeloma Drug Combination
--------------------------------------------------------------------------------

- C4 Therapeutics and Pfizer signed a clinical trial collaboration and supply agreement for elranatamab and cemsidomide.
- Pfizer will supply elranatamab (ELREXFIO) at no cost for a Phase 1b trial in relapsed/refractory multiple myeloma.
- The Phase 1b trial will evaluate cemsidomide, dexamethasone, and elranatamab as second-line or later therapy.
- Trial expected to start in Q2 2026; C4 Therapeutics sponsors and conducts the trial.
- C4 Therapeutics CEO noted potential to improve outcomes and combine with a growing standard-of-care bispecific.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025043290/0001628280-25-043290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025043290/cccc-20251001.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-043290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer